Free
Clinical Science  |   June 1999
Augmentation of the Rocuronium-induced Neuromuscular Block by the Acutely Administered Phenytoin
Author Notes
  • (Spacek, Neiger) Staff Anesthesiologist, Department of Anesthesia and General Intensive Care (B), University of Vienna.
  • (Nickl) Resident, Department of Anesthesia, University of Regensburg.
  • (Nigrovic) Professor Emeritus, Departments of Anesthesiology and Pharmacology, Medical College of Ohio.
  • (Ullrich) Staff Neurosurgeon, Department of Neurosurgery, University of Regensburg.
  • (Weindlmayr-Goettel) Staff Chemist, Department of Anesthesia and General Intensive Care (B), University of Vienna.
  • (Schwall) Staff Anesthesiologist, Department of Anesthesia, University of Regensburg.
  • (Taeger) Professor and Head, Department of Anesthesia, University of Regensburg.
  • (Kress) Professor and Head, Department of Anesthesia and General Intensive Care (B), University of Vienna.
  • Received from The University of Vienna, Vienna, Austria; the University of Regensburg, Regensburg, Germany; and the Medical College of Ohio, Toledo, Ohio. Submitted for publication October 14, 1998. Accepted for publication January 19, 1999. Supported by Organon Teknika International, Turnhout, Belgium, and monitored by IMRO, AW Berghem, The Netherlands.
  • Address reprint requests to Dr. Spacek: Department of Anesthesia and General Intensive Care (B), University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. Address electronic mail to: Anna.Spacek@univie.ac.at
Article Information
Clinical Science
Clinical Science   |   June 1999
Augmentation of the Rocuronium-induced Neuromuscular Block by the Acutely Administered Phenytoin
Anesthesiology 6 1999, Vol.90, 1551-1555.. doi:
Anesthesiology 6 1999, Vol.90, 1551-1555.. doi:
Key Words: Acute administration; anticonvulsant; drug interaction; muscle relaxant.
THE acute effects of phenytoin on the neuromuscular block produced by a nondepolarizing muscle relaxant apparently differ from those after long-term administration of anticonvulsant drugs. In humans, the acute administration of phenytoin enhanced [1] and the long-term intake shortened [2,3] the neuromuscular block produced by vecuronium. If the acute effects reported by Gray et al. [1] could be reproduced with yet another nondepolarizing muscle relaxant, the argument for an acute pharmacodynamic interaction between phenytoin and the nondepolarizing muscle relaxants would be strengthened. The goal of the current study was to evaluate the effect of acutely administered phenytoin on the preestablished neuromuscular block produced by an infusion of rocuronium.
Materials and Methods
The study was approved by the Institutional Review Board of the University Hospital of Regensburg, Germany, and written informed consent was obtained from each patient. Twenty patients scheduled to undergo elective craniotomy for tumors or a cerebrovascular anomaly were evaluated. Fifteen patients required intraoperative anticonvulsant prophylaxis with phenytoin (group 1), whereas five patients did not require phenytoin prophylaxis and served as controls (0.9% saline infusion, group 2). All 20 patients (classified as American Society of Anesthesiology physical status I or II) had normal cardiac, renal, pulmonary, and hepatic function. Patients with neuromuscular disease or who were taking drugs known to alter the neuromuscular transmission were excluded from the study. Also excluded were patients with psychiatric diseases and those with a recent history of alcohol or drug abuse.
The patients were premedicated with 20 mg oral chlorazepam 1 h before surgery. After preoxygenation, anesthesia was induced with 3-5 mg/kg thiopental and 3-5 [micro sign]g/kg fentanyl injected intravenously. After tracheal intubation, the lungs were mechanically ventilated to keep the end-tidal carbon dioxide level between 30 and 35 mmHg. Anesthesia was maintained with 65% nitrous oxide in oxygen and 1% end-tidal isoflurane and supplemented with fentanyl as judged by clinical criteria. The esophageal temperature was maintained at more than 36 [degree sign]C using convective heating. Patient monitoring included electrocardiography, invasive measurement of arterial blood pressure, pulse oximetry, end-tidal capnography, and esophageal and skin temperatures.
Neuromuscular transmission was monitored using the Datex Neuromuscular Transmission Monitor (Datex Instrumentarium Corp., Helsinki, Finland). Every 20 s the monitor delivered to the ulnar nerve via surface electrodes a train-of-four supramaximal stimuli at a rate of 2 Hz, with each stimulus lasting 100 [micro sign]s. The patient's hand was secured carefully to a padded board to minimize movement and was kept warm (>32 [degree sign]C as measured using a skin thermistor). Electromyographic data from the abductor digiti minimi muscle were recorded in each patient for a 3- to 5-min period after anesthesia was induced, but before rocuronium was administered. A stable baseline was obtained in each patient. Thereafter, a bolus dose of rocuronium (0.9 mg/kg = 3 x ED95) was injected intravenously to facilitate tracheal intubation.
When the first twitch in the train (T1) reappeared, rocuronium administration began with an intravenous infusion at an initial rate of 8 +/- 3 [micro sign]g [middle dot] kg-1[middle dot] min-1. To obtain and maintain a steady state neuromuscular block of 85-90%, the infusion rate was adjusted in steps of 1 [micro sign]g [middle dot] kg-1[middle dot] min-1. The study was initiated after a stable T1amplitude was established at between 10 and 15% for 30 min without changes in the infusion rate or the inhaled concentration of isoflurane. During the preinfusion study period, which lasted 15 min, the magnitude of the twitch was recorded every 5 min. The four sampling times were labeled -15, -10, -5, and 0 min. At each sampling time, nine measurements of T1were recorded and two arterial blood samples were collected. One sample of 8 ml was placed in a heparin-prepared tube containing 2 ml NaH2PO4, 1 M, and was used to measure the rocuronium concentration in plasma, whereas another sample of 6 ml blood was used to measure the protein-bound fraction of rocuronium. An infusion of either phenytoin or saline was started at time zero.
Phenytoin was administered to the patients of group 1 in a concentration of 25 mg/ml at a rate of 25-50 mg/min to a total dose of 10 mg/kg. The infusion rate was slowed when the mean arterial pressure decreased to less than 80% or when relevant changes, such as bradycardia or a block, appeared on the electrocardiogram. Patients in group 2 received an infusion of saline, 0.9% (0.4 ml/kg), at a rate of 1 ml/min. The infusions were completed within 15-30 min. The magnitude of the first twitch was recorded (nine observations at each sampling time) and arterial blood samples were collected 10, 20, 40, and 60 min after the start of the infusion. Blood samples were centrifuged immediately (4 [degree sign]C at 3,000 rpm for 10 min), and the plasma was stored at -70 [degree sign]C until the total and the protein-free concentration of rocuronium was measured using a high-performance liquid chromatography method that can distinguish the parent drug and its metabolites. [4] No metabolites could be detected in the plasma samples. The protein-free fraction of rocuronium was obtained by centrifugation (2,000 rpm for 60 min) of serum and ultrafiltration using Centrisart I membranes (20,000 D, Sartorius, Germany), according to the method reported by Jacob et al. [5] The percentage of protein-bound rocuronium was calculated from the difference between total and free levels. In addition, separate blood samples (8 ml each) were collected from patients in group 1 before and 20, 40, and 60 min after the start of the phenytoin infusion to determine the phenytoin concentrations by fluorescence polarization immunoassay.
Statistical Analyses
The first twitch was transformed to its logit (logit T1= 1n[T1/ (100 - T1)]). The nine transforms for each sampling period were averaged and the arithmetic means were used for further analysis. T1recorded as 0% was set to 0.1% to obtain a usable logit transform. The total plasma concentrations of rocuronium or phenytoin and the percentage of rocuronium bound to plasma proteins were first converted to their logarithms and the transforms were used for statistical analyses. The transformed data were subdivided into two groups, a saline and a phenytoin group, and each group was further subdivided into two periods, that before and that after the start of infusion. The data in the four subgroups were frequently non-normally distributed as estimated by the Levene test for homogeneity of variances. In these instances, both the parametric (mean, SD, and t test) and nonparametric analyses (median, lower and upper quartiles, Mann-Whitney U test, and the Spearman rank order correlation) were performed and the results of both analyses are reported. We decided whether a result might be attributed to a chance observation based on a probability of 5% or more associated with a chance observation (i.e., P < 0.05).
Results
Seven women and eight men who were 45.1 +/- 11.4 yr old (mean +/- SD) and weighed 77.6 +/- 13.5 kg were studied in group 1; five patients were included in group 2, four women and one man who were 38.8 +/- 16.4 yr old and weighed 74.8 +/- 8.2 kg.
(Figure 1) shows the magnitudes of the first twitch in individual patients as a function of time. A marked decrease in the twitch size is evident in patients receiving phenytoin but not in those receiving saline.
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
×
(Table 1) is a numeric summary of the data. Before the infusions were started, the twitch sizes were within the range specified in the experimental design, albeit slightly smaller in the phenytoin than in the saline group. After the start of the infusions, the twitch size did not change in the saline group but was markedly decreased in the phenytoin group.
Table 1. Twitch (T1in %)
Image not available
Table 1. Twitch (T1in %)
×
The wider spread of the twitch sizes in this subgroup may be explained by an association of the smaller twitch sizes with the longer times elapsed after the start of the phenytoin infusion (Spearman rank order correlation, P < 0.001).
(Figure 2) shows the time course of the total plasma concentration of rocuronium in individual patients. Inspection of the data reveals no marked differences between the saline and phenytoin groups or between the pre- and postinfusion periods within each group.
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
×
(Table 2) summarizes the binding of rocuronium to plasma proteins. The extent of protein binding was not altered after the saline infusion. The bound fraction was, however, slightly decreased after the phenytoin infusion.
Table 2. Percent of Rocuronium Bound to Plasma Proteins
Image not available
Table 2. Percent of Rocuronium Bound to Plasma Proteins
×
In most patients, the peak total plasma concentrations of phenytoin were established by 20 min after the start of the infusion, and the concentrations decreased thereafter.
Discussion
The results clearly show that a stable neuromuscular block produced by a constant infusion of rocuronium is augmented by an acute administration of phenytoin. Phenytoin rapidly decreases the twitch size but does not change either the total concentration of rocuronium in plasma or the extent of its binding to plasma proteins. The results confirm earlier findings with vecuronium in patients, [1] and with d-tubocurarine [6] and pancuronium or fazadinium in rats [7] after acute administration of phenytoin, [1,6] carbamazepine, or valproic acid. [7] 
Currently available information about the interaction between anticonvulsants and nondepolarizing muscle relaxants may be summarized briefly as follows: Acute administration of anticonvulsants augments neuromuscular block, whereas chronic administration reduces the duration of action of all aminosteroidal muscle relaxants (vecuronium, [2,3] pancuronium, [8,9] pipecuronium, [10] and rocuronium, [11-15]), metocurine, [16] and doxacurium [17] but not of the ester benzylisoquinoline relaxants atracurium [3,18] (with a possible exception [19]) and mivacurium. [20,21] Possible explanations of the opposite effects of the acute and chronic administration of anticonvulsant drugs include a pharmacodynamic or a pharmacokinetic interaction, or both. We believe that the pharmacokinetic explanation, such as through an enhanced systemic clearance of the relaxants, [11,12,22] accounts well for the effects of chronic administration of anticonvulsants, and the pharmacodynamic explanation accounts for the acute effects of these drugs.
A plausible pharmacodynamic explanation for the clinical findings with muscle relaxants in patients treated acutely with phenytoin or carbamazepine may be based on the in vitro effects of these drugs on neuromuscular transmission. Although the precise mechanisms are still unclear, phenytoin was reported consistently to decrease the stimulus-induced release of acetylcholine from the motor nerve terminals. [23-28] The extent of this acute in vitro inhibition by clinically relevant concentrations of phenytoin was estimated from the quantal content of acetylcholine. The content was decreased by approximately 20% in the frog neuromuscular junction [25] and by 50% in a mouse muscle. [24] A diminution of the presynaptic activity induced by phenytoin, described as membrane stabilization, [23] also was documented in cats in vivo. [29,30] Succinylcholine-induced repetitive firing of the motor nerve terminal was suppressed, whereas the equieffective doses of succinylcholine were reduced (leftward shift of the dose-response curve) by a 30-mg/kg intravenous injection of phenytoin. The findings indicate a diminished transmitter output. We suggest that our findings may be explained by postulating that phenytoin acutely reduces the stimulus-induced release of acetylcholine.
Although the decrease in the twitch size by phenytoin develops rapidly, it showed no association with the plasma concentration of the drug. The lack of correlation (hysteresis) probably indicates that the drug is only slowly distributed in the body. Thus, the peak phenytoin concentration in the muscle tissue and in the synaptic clefts might be delayed. The duration of the postulated presynaptic effect of phenytoin is not known.
In conclusion, our study clearly shows that an acute administration of phenytoin augments the steady state neuromuscular block produced by rocuronium without influencing the plasma concentration of rocuronium or the extent of its protein binding.
The authors thank the staff of the Departments of Anesthesiology and Neurosurgery, University of Regensburg, Germany, for their cooperation.
REFERENCES
Gray HSTJ, Slater RM, Pollard BJ: The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade. Anesthesia 1989; 44:379-81.
Whalley DG, Ebrahim ZY: Influence of carbamazepine on the dose-response relationship of vecuronium. Br J Anaesth 1994; 72:124-6
Ornstein E, Matteo RS, Schwartz AE, Silverberg PA, Young WL, Diaz J: The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987; 67:191-6
Kleef UW, Proost JH, Roggeveld J, Wierda JM: Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 1993; 621:65-76
Jacob D, Grignon S, Attolini L, Gantenbein M, Bruguerolle B: Effects of calcium antagonists on binding of local anesthetics to plasma proteins and erythrocytes in mice. Pharmacology 1996; 53:219-23
Gandhi IC, Jindal MN, Patel VK: Mechanism of neuromuscular blockade with some antiepileptic drugs. Arzneimittelforschung 1976; 26:258-61
Blanc-Bimar MC, Jadot G, Bruguerolle B, Valli M, Bouyard P: Modifications de la curarisation apres administration aigue de deux antiepileptiques. (Modification of curarization after acute administration of 2 antiepileptic drugs.) Ann Anesthesiol Fr 1979; 20:685-90
Hickey DR, Sangwan S, Bevan JC: Phenytoin-induced resistance to pancuronium. Use of atracurium infusion in management of a neurosurgical patient. Anaesthesia 1988; 43:757-9
Liberman BA, Norman P, Hardy BG: Pancuronium-phenytoin interaction: A case of decreased duration of neuromuscular blockade. Int J Clin Pharmacol 1988; 26:371-4
Jellish WS, Modica PA, Tempelhoff R: Accelerated recovery from pipecuronium in patients treated with anticonvulsant therapy. J Clin Anesth 1993; 5:105-8
Szenohradszky J, Caldwell JE, Sharma ML, Gruenke LD, Miller RD: Interaction of rocuronium bromide (ORG 9426) and phenytoin in a patient undergoing cadaver renal transplantation: A possible pharmacokinetic mechanism? Anesthesiology 1994; 80:1167-70
Driessen JJ, Robertson EN, Booij LHDJ, Vree TB: Accelerated recovery and disposition from rocuronium in an end-stage renal failure patient on chronic anticonvulsant therapy with sodium valproate and primidone. Br J Anaesth 1998; 80:386-8
Baraka A, Idriss N: Resistance to rocuronium in an epileptic patient on long-term carbamazepine therapy-A case report. Middle East J Anesthesiol 1996; 13:561-4
Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P: Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs. Br J Anaesthesia 1997; 78:90-1
Spacek A, Neiger FX, Krenn CG, Hoerauf K, Kress HG: Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 1999; 90:109-12
Ornstein E, Matteo RS, Young WL, Diaz J: Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. Anesthesiology 1985; 63:294-8
Ornstein E, Matteo RS, Weinstein JA, Halevy JD, Young WL, Abou Donia MM: Accelerated recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic anticonvulsant therapy. J Clin Anesth 1991; 3:108-11
Spacek A, Neiger FX, Spiss CK, Kress HG: Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine. Acta Anaesthesiol Scand 1997; 41:1308-11
Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL: Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990; 71:665-9
Spacek A, Neiger FX, Spiss CK, Kress HG: Chronic carbamazepine therapy does not influence the mivacurium-induced neuromuscular block. Br J Anaesth 1996; 77:500-2
Jellish WS, Thalji Z, Brundidge PK, Tempelhoff R: Recovery from mivacurium-induced neuromuscular blockade is not affected by anticonvulsant therapy. J Neurosurg Anesth 1996; 8:4-8
Alloul K, Whalley DG, Shutway F, Ebrahim Z, Varin F: Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology 1996; 84:330-9
Yaari Y, Selzer ME, Pincus JH: Phenytoin: Mechanisms of its anticonvulsant action. Ann Neurol 1986; 20:171-84
Gage PW, Lonergan M, Torda TA: Presynaptic and postsynaptic depressant effects of phenytoin sodium at the neuromuscular junction. Br J Pharmacol 1980; 69:119-21
Yaari Y, Pincus JH, Argov Z: Phenytoin and transmitter release at the neuromuscular junction of the frog. Brain Res 1979; 160:479-87
Yaari Y, Pincus JH, Argov T: Depression of synaptic transmission by diphenylhydantoin. Ann Neurol 1997; 1:334-8
Anderson GD: A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1989; 32:554-63
Norris FH Jr, Colella J, McFarlin D: Effect of diphenylhydantoin on neuromuscular synapse. Neurology 1964; 14:869-76
Hartman GS, Fiamengo SA, Riker WF: Succinylcholine: Mechanism of fasciculations and their prevention by d-tubocurarine or diphenylhydantoin. Anesthesiology 1986; 65:405-13
Raines A, Standaert FG: Pre- and postjunctional effects of diphenylhydantoin at the cat soleus neuromuscular junction. J Pharmacol Exp Ther 1966; 153:361-6
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
Figure 1. The time course of the first twitch in patients receiving a constant infusion of rocuronium. Time 0 min denotes the start of infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles). Phenytoin in a dose of 10 mg/kg was infused during the period of approximately 30 min.
×
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
Figure 2. The time course of the total plasma concentrations of rocuronium in patients receiving a constant infusion of the drug. At time 0 min, an additional infusion of saline (n = 5, empty circles) or phenytoin (n = 15, filled circles) was initiated.
×
Table 1. Twitch (T1in %)
Image not available
Table 1. Twitch (T1in %)
×
Table 2. Percent of Rocuronium Bound to Plasma Proteins
Image not available
Table 2. Percent of Rocuronium Bound to Plasma Proteins
×